Diego Arango

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8595210/publications.pdf

Version: 2024-02-01

95 papers	6,033 citations	81743 39 h-index	71532 76 g-index
100 all docs	100 docs citations	100 times ranked	10262 citing authors

#	Article	IF	Citations
1	Colorectal cancer inhibition by BET inhibitor JQ1 is MYC-independent and not improved by nanoencapsulation. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 171, 39-49.	2.0	3
2	Epithelial de-differentiation triggered by co-ordinate epigenetic inactivation of the EHF and CDX1 transcription factors drives colorectal cancer progression. Cell Death and Differentiation, 2022, 29, 2288-2302.	5.0	6
3	Polymeric micelles targeted against CD44v6 receptor increase niclosamide efficacy against colorectal cancer stem cells and reduce circulating tumor cells in vivo. Journal of Controlled Release, 2021, 331, 198-212.	4.8	35
4	Identification of ZBTB18 as a novel colorectal tumor suppressor gene through genome-wide promoter hypermethylation analysis. Clinical Epigenetics, 2021, 13, 88.	1.8	5
5	Dickkopf-1 Inhibition Reactivates Wnt/Î²-Catenin Signaling in Rhabdomyosarcoma, Induces Myogenic Markers In Vitro and Impairs Tumor Cell Survival In Vivo. International Journal of Molecular Sciences, 2021, 22, 12921.	1.8	2
6	Zileutonâ„¢ loaded in polymer micelles effectively reduce breast cancer circulating tumor cells and intratumoral cancer stem cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 24, 102106.	1.7	44
7	A Molecular Mechanism Underlying Genotypeâ€Specific Intrahepatic Cholestasis Resulting From MYO5B Mutations. Hepatology, 2020, 72, 213-229.	3.6	30
8	Intracellular Delivery of Anti-SMC2 Antibodies against Cancer Stem Cells. Pharmaceutics, 2020, 12, 185.	2.0	16
9	Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemiaâ€“Related Head and Neck Cancer. Clinical Cancer Research, 2020, 26, 3044-3057.	3.2	23
10	PVT1 Long Non-coding RNA in Gastrointestinal Cancer. Frontiers in Oncology, 2020, 10, 38.	1.3	43
11	Pivotal Role of AKT2 during Dynamic Phenotypic Change of Breast Cancer Stem Cells. Cancers, 2019, 11, 1058.	1.7	32
12	Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients. Cancers, 2019, 11, 1540.	1.7	19
13	Glucocorticoids and myosin5b loss of function induce heightened PKA signaling in addition to membrane traffic defects. Molecular Biology of the Cell, 2019, 30, 3076-3089.	0.9	11
14	Loss of MYO5B expression deregulates late endosome size which hinders mitotic spindle orientation. PLoS Biology, 2019, 17, e3000531.	2.6	10
15	Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer. Journal of Controlled Release, 2019, 307, 108-138.	4.8	49
16	Abstract 840: Identification of novel colorectal tumor suppressor genes through genome-wide promoter hypermethylation analysis. , 2019, , .		0
17	AKT2 siRNA delivery with amphiphilic-based polymeric micelles show efficacy against cancer stem cells. Drug Delivery, 2018, 25, 961-972.	2.5	32
18	DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis. Scientific Reports, 2018, 8, 1767.	1.6	11

#	Article	IF	Citations
19	Efficient EFGR mediated siRNA delivery to breast cancer cells by Cetuximab functionalized PluronicÂ® F127/Gelatin. Chemical Engineering Journal, 2018, 340, 81-93.	6.6	26
20	Dynamism, Sensitivity, and Consequences of Mesenchymal and Stem-Like Phenotype of Cancer Cells. Stem Cells International, 2018, 2018, 1-12.	1.2	17
21	Silencing of adaptor protein <scp>SH</scp>3<scp>BP</scp>2 reduces <scp>KIT</scp>/<scp>PDGFRA</scp> receptors expression and impairs gastrointestinal stromal tumors growth. Molecular Oncology, 2018, 12, 1383-1397.	2.1	12
22	Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer. British Journal of Cancer, 2018, 118, 106-116.	2.9	24
23	Rational Design of a siRNA Delivery System: ALOX5 and Cancer Stem Cells as Therapeutic Targets. Precision Nanomedicine, 2018, 1, 86-105.	0.4	6
24	Investigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer. Scientific Reports, 2017, 7, 41576.	1.6	9
25	Loss of the EPH receptor B6 contributes to colorectal cancer metastasis. Scientific Reports, 2017, 7, 43702.	1.6	25
26	Cancer stem cells and personalized cancer nanomedicine. Nanomedicine, 2016, 11, 307-320.	1.7	27
27	Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells. Molecular Cancer Therapeutics, 2016, 15, 1217-1226.	1.9	71
28	Myo5b knockout mice as a model of microvillus inclusion disease. Scientific Reports, 2015, 5, 12312.	1.6	52
29	PTPRD is Homozygously Deleted and Epigenetically Downregulated in Human Hepatocellular Carcinomas. OMICS A Journal of Integrative Biology, 2015, 19, 220-229.	1.0	14
30	Highly Expressed Genes in Rapidly Proliferating Tumor Cells as New Targets for Colorectal Cancer Treatment. Clinical Cancer Research, 2015, 21, 3695-3704.	3.2	25
31	Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1883-1892.	1.7	69
32	Eph Receptors. , 2015, , 1549-1551.		0
33	Abstract 2058: RHOA inactivation enhances Wnt signaling and promotes colorectal cancer. , 2015, , .		0
34	RHOA inactivation enhances Wnt signalling and promotes colorectal cancer. Nature Communications, 2014, 5, 5458.	5.8	95
35	The Intestinal Epithelial Cell Differentiation Marker Intestinal Alkaline Phosphatase (ALPi) Is Selectively Induced by Histone Deacetylase Inhibitors (HDACi) in Colon Cancer Cells in a Kruppel-like Factor 5 (KLF5)-dependent Manner. Journal of Biological Chemistry, 2014, 289, 25306-25316.	1.6	53
36	Colorectal Cancer Cell Lines Are Representative Models of the Main Molecular Subtypes of Primary Cancer. Cancer Research, 2014, 74, 3238-3247.	0.4	317

#	Article	IF	Citations
37	Abstract 5172: Whole exome mutation landscape of 70 commonly used colorectal cancer cell lines. , 2014, , .		0
38	Brush border myosin Ia inactivation in gastric but not endometrial tumors. International Journal of Cancer, 2013, 132, 1790-1799.	2.3	21
39	Brush border Myosin Ia has tumor suppressor activity in the intestine. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 1530-1535.	3.3	60
40	Human SMC2 Protein, a Core Subunit of Human Condensin Complex, Is a Novel Transcriptional Target of the WNT Signaling Pathway and a New Therapeutic Target. Journal of Biological Chemistry, 2012, 287, 43472-43481.	1.6	39
41	Villin Expression Is Frequently Lost in Poorly Differentiated Colon Cancer. American Journal of Pathology, 2012, 180, 1509-1521.	1.9	28
42	Candidate driver genes in microsatelliteâ€unstable colorectal cancer. International Journal of Cancer, 2012, 130, 1558-1566.	2.3	99
43	Abstract 4316: Villin expression is frequently lost in colon cancers with microsatellite instability.. , 2012, , .		0
44	Eph Receptors. , 2011, , 1268-1269.		0
45	Mutations in the Circadian Gene CLOCK in Colorectal Cancer. Molecular Cancer Research, 2010, 8, 952-960.	1.5	77
46	Apoptotic Sensitivity of Colon Cancer Cells to Histone Deacetylase Inhibitors Is Mediated by an Sp1/Sp3-Activated Transcriptional Program Involving Immediate-Early Gene Induction. Cancer Research, 2010, 70, 609-620.	0.4	98
47	Aprataxin Tumor Levels Predict Response of Colorectal Cancer Patients to Irinotecan-based Treatment. Clinical Cancer Research, 2010, 16, 2375-2382.	3.2	35
48	Abstract 4921: Selective promoter methylation of the cell differentiation marker, intestinal alkaline phosphatase (iALP), in microsatellite unstable colon cancer. , 2010, , .		0
49	The Receptor Tyrosine Kinase EPHB4 Has Tumor Suppressor Activities in Intestinal Tumorigenesis. Cancer Research, 2009, 69, 7430-7438.	0.4	58
50	Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. Clinical Cancer Research, 2009, 15, 7642-7651.	3.2	395
51	An A13 Repeat within the 3â€²-Untranslated Region of Epidermal Growth Factor Receptor (EGFR) Is Frequently Mutated in Microsatellite Instability Colon Cancers and Is Associated with Increased EGFR Expression. Cancer Research, 2009, 69, 7811-7818.	0.4	34
52	Expression of seleniumâ€binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer. Molecular Nutrition and Food Research, 2008, 52, 1289-1299.	1.5	75
53	Germline hypermethylation of the APC promoter is not a frequent cause of familial adenomatous polyposis in APC/MUTYH mutation negative families. International Journal of Cancer, 2008, 122, 1422-1425.	2.3	15
54	Transforming pathways unleashed by a HDAC2 mutation in human cancer. Oncogene, 2008, 27, 4008-4012.	2.6	33

#	Article	IF	Citations
55	Unregulated smooth-muscle myosin in human intestinal neoplasia. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5513-5518.	3.3	77
56	PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab. Cancer Research, 2008, 68, 1953-1961.	0.4	435
57	HDAC4 Promotes Growth of Colon Cancer Cells via Repression of p21. Molecular Biology of the Cell, 2008, 19, 4062-4075.	0.9	188
58	EPH receptors in cancer. Histology and Histopathology, 2008, 23, 1011-23.	0.5	37
59	Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis. Oncogene, 2007, 26, 312-320.	2.6	136
60	High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability. Oncogene, 2007, 26, 308-311.	2.6	38
61	Decrease in c-Myc activity enhances cancer cell sensitivity to vinblastine. Anti-Cancer Drugs, 2006, 17, 181-187.	0.7	21
62	A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nature Genetics, 2006, 38, 566-569.	9.4	254
63	Modeling tumor predisposingFHmutations in yeast: Effects on fumarase activity, growth phenotype and gene expression profile. International Journal of Cancer, 2006, 118, 1340-1345.	2.3	7
64	Distinct expression profile in fumarate-hydratase-deficient uterine fibroids. Human Molecular Genetics, 2006, 15, 97-103.	1.4	67
65	Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells. Journal of Medical Genetics, 2006, 44, 75-80.	1.5	25
66	Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer. Journal of Biological Chemistry, 2006, 281, 13548-13558.	1.6	486
67	EPHB4 and Survival of Colorectal Cancer Patients. Cancer Research, 2006, 66, 8943-8948.	0.4	80
68	Reply to the Letter to the Editor by Watanabe et al.. Clinical Cancer Research, 2006, 12, 1654.1-1655.	3.2	0
69	Na+/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: Molecular characterization of SMCT. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7270-7275.	3.3	98
70	7q deletion mapping and expression profiling in uterine fibroids. Oncogene, 2005, 24, 6545-6554.	2.6	33
71	SMAD4 Levels and Response to 5-Fluorouracil in Colorectal Cancer. Clinical Cancer Research, 2005, 11, 6311-6316.	3.2	89
72	Mutations in Two Short Noncoding Mononucleotide Repeats in Most Microsatellite-Unstable Colorectal Cancers. Cancer Research, 2005, 65, 4607-4613.	0.4	16

#	Article	IF	Citations
73	Mechanisms of Inactivation of the Receptor Tyrosine Kinase EPHB2 in Colorectal Tumors. Cancer Research, 2005, 65, 10170-10173.	0.4	84
74	SMAD4 as a Prognostic Marker in Colorectal Cancer. Clinical Cancer Research, 2005, 11, 2606-2611.	3.2	172
75	Gene expression signatures for colorectal cancer microsatellite status and HNPCC. British Journal of Cancer, 2005, 92, 2240-2248.	2.9	70
76	Gene expression profiling of intestinal epithelial cell maturation along the crypt-villus axis. Gastroenterology, 2005, 128, 1081-1088.	0.6	171
77	Gene-Expression Profiling Predicts Recurrence in Dukesâ€™ C Colorectal Cancer. Gastroenterology, 2005, 129, 874-884.	0.6	119
78	Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Human Molecular Genetics, 2004, 13, 2303-2311.	1.4	127
79	Tumor necrosis factor-Î± related gene response to Epothilone B in ovarian cancer. Gynecologic Oncology, 2004, 93, 19-26.	0.6	12
80	Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. British Journal of Cancer, 2004, 91, 1931-1946.	2.9	212
81	Customizing chemotherapy for colon cancer: the potential of gene expression profiling. Drug Resistance Updates, 2004, 7, 209-218.	6.5	15
82	Microarray analysis in the clinical management of cancer. Hematology/Oncology Clinics of North America, 2003, 17, 377-387.	0.9	18
83	Oncogenic Ki-Ras Inhibits the Expression of Interferon-responsive Genes through Inhibition of STAT1 and STAT2 Expression. Journal of Biological Chemistry, 2003, 278, 46278-46287.	1.6	61
84	c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. British Journal of Cancer, 2003, 89, 1757-1765.	2.9	71
85	Application of Gene Expression Profiling to Colon Cell Maturation, Transformation and Chemoprevention. Journal of Nutrition, 2003, 133, 2410S-2416S.	1.3	14
86	TR3/Nur77 in colon cancer cell apoptosis. Cancer Research, 2003, 63, 5401-7.	0.4	89
87	Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Research, 2003, 63, 8791-812.	0.4	154
88	A gene expression profile that defines colon cell maturation in vitro. Cancer Research, 2002, 62, 4791-804.	0.4	93
89	Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. Cancer Research, 2002, 62, 6006-10.	0.4	47
90	Diagnostic ultrasound induces change within numbers of cryptal mitotic and apoptotic cells in small intestine. Life Sciences, 2001, 68, 1471-1475.	2.0	20

#	Article	IF	Citations
91	BB-10010, an analog of macrophage inflammatory protein-1alpha, protects murine small intestine against radiation. Digestive Diseases and Sciences, 2001, 46, 2608-2614.	1.1	13
92	Clinical Response to Fluorouracil andp53. New England Journal of Medicine, 2001, 345, 1065-1066.	13.9	3
93	Dose-effect relationship of BB-10010/MIP-1 alpha on proliferation in murine small intestinal epithelium: single and double administration protocols. Digestive Diseases and Sciences, 2000, 45, 2306-2312.	1.1	2
94	BB-10010, an Analogue of Macrophage Inflammatory Protein-1 Alpha, Reduces Proliferation in Murine Small-Intestinal Crypts. Scandinavian Journal of Gastroenterology, 1999, 34, 68-72.	0.6	8
95	Cell-cycle perturbations following low-dose x-rays. Radiography, 1999, 5, 111-115.	1.1	0